59 related articles for article (PubMed ID: 36860694)
1. Facts and Hopes in Immunotherapy Strategies Targeting Antigens Derived from KRAS Mutations.
Linette GP; Bear AS; Carreno BM
Clin Cancer Res; 2024 May; 30(10):2017-2024. PubMed ID: 38266167
[TBL] [Abstract][Full Text] [Related]
2. Targeting KRAS
Ai Q; Li F; Zou S; Zhang Z; Jin Y; Jiang L; Chen H; Deng X; Peng C; Mou N; Wen C; Shen B; Zhan Q
Front Immunol; 2023; 14():1161538. PubMed ID: 37287989
[TBL] [Abstract][Full Text] [Related]
3. Antigen presentation in cancer - mechanisms and clinical implications for immunotherapy.
Yang K; Halima A; Chan TA
Nat Rev Clin Oncol; 2023 Sep; 20(9):604-623. PubMed ID: 37328642
[TBL] [Abstract][Full Text] [Related]
4. Dominant neoantigen verification in hepatocellular carcinoma by a single-plasmid system coexpressing patient HLA and antigen.
Chen P; Chen D; Bu D; Gao J; Qin W; Deng K; Ren L; She S; Xu W; Yang Y; Xie X; Liao W; Chen H
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37076248
[TBL] [Abstract][Full Text] [Related]
5. Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma.
Yousef A; Yousef M; Chowdhury S; Abdilleh K; Knafl M; Edelkamp P; Alfaro-Munoz K; Chacko R; Peterson J; Smaglo BG; Wolff RA; Pant S; Lee MS; Willis J; Overman M; Doss S; Matrisian L; Hurd MW; Snyder R; Katz MHG; Wang H; Maitra A; Shen JP; Zhao D
NPJ Precis Oncol; 2024 Feb; 8(1):27. PubMed ID: 38310130
[TBL] [Abstract][Full Text] [Related]
6. Tuning the ignition of CAR: optimizing the affinity of scFv to improve CAR-T therapy.
Duan Y; Chen R; Huang Y; Meng X; Chen J; Liao C; Tang Y; Zhou C; Gao X; Sun J
Cell Mol Life Sci; 2021 Dec; 79(1):14. PubMed ID: 34966954
[TBL] [Abstract][Full Text] [Related]
7. T Cell Receptors for Gene Transfer in Adoptive T Cell Therapy.
Sharma P; Kranz DM
Crit Rev Immunol; 2019; 39(2):105-122. PubMed ID: 31679251
[TBL] [Abstract][Full Text] [Related]
8. Chimeric Antigen Receptors Directed at Mutant KRAS Exhibit an Inverse Relationship Between Functional Potency and Neoantigen Selectivity.
Tokatlian T; Asuelime GE; Naradikian MS; Mock JY; Daris ME; Martin AD; Toledo Warshaviak D; Kamb A; Hamburger AE
Cancer Res Commun; 2022 Jan; 2(1):58-65. PubMed ID: 36860694
[TBL] [Abstract][Full Text] [Related]
9. High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D.
Sim MJW; Lu J; Spencer M; Hopkins F; Tran E; Rosenberg SA; Long EO; Sun PD
Proc Natl Acad Sci U S A; 2020 Jun; 117(23):12826-12835. PubMed ID: 32461371
[TBL] [Abstract][Full Text] [Related]
10. KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors.
Lu D; Chen Y; Jiang M; Wang J; Li Y; Ma K; Sun W; Zheng X; Qi J; Jin W; Chen Y; Chai Y; Zhang CWH; Liang H; Tan S; Gao GF
Nat Commun; 2023 Oct; 14(1):6389. PubMed ID: 37828002
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic high affinity T cell receptor targeting a KRAS
Poole A; Karuppiah V; Hartt A; Haidar JN; Moureau S; Dobrzycki T; Hayes C; Rowley C; Dias J; Harper S; Barnbrook K; Hock M; Coles C; Yang W; Aleksic M; Lin AB; Robinson R; Dukes JD; Liddy N; Van der Kamp M; Plowman GD; Vuidepot A; Cole DK; Whale AD; Chillakuri C
Nat Commun; 2022 Sep; 13(1):5333. PubMed ID: 36088370
[TBL] [Abstract][Full Text] [Related]
12. Identification and affinity enhancement of T-cell receptor targeting a KRAS
Zhang M; Xu W; Luo L; Guan F; Wang X; Zhu P; Zhang J; Zhou X; Wang F; Ye S
Commun Biol; 2024 Apr; 7(1):512. PubMed ID: 38684865
[TBL] [Abstract][Full Text] [Related]
13. Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma.
Zhang C; Wang L; Zhang Q; Shen J; Huang X; Wang M; Huang Y; Chen J; Xu Y; Zhao W; Qi Y; Li Y; Ou Y; Yang Z; Qian C
Front Immunol; 2023; 14():1182409. PubMed ID: 37304295
[TBL] [Abstract][Full Text] [Related]
14. Systematic discovery and validation of TÂ cell targets directed against oncogenic KRAS mutations.
Choi J; Goulding SP; Conn BP; McGann CD; Dietze JL; Kohler J; Lenkala D; Boudot A; Rothenberg DA; Turcott PJ; Srouji JR; Foley KC; Rooney MS; van Buuren MM; Gaynor RB; Abelin JG; Addona TA; Juneja VR
Cell Rep Methods; 2021 Sep; 1(5):100084. PubMed ID: 35474673
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
